trihexyphenidyl has been researched along with Cardiovascular Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, S; Li, J; Li, X; Liang, H; Lv, Y; Tang, X; Wang, M; Xiao, L; Zhang, J; Zou, H | 1 |
| Pomara, N; Sidtis, J | 1 |
2 other study(ies) available for trihexyphenidyl and Cardiovascular Diseases
| Article | Year |
|---|---|
Central inhibition prevents the in vivo acute toxicity of harmine in mice.
Topics: Acetylcholinesterase; Anesthetics; Animals; Cardiovascular Diseases; Central Nervous System Diseases; Cholinergic Antagonists; Dose-Response Relationship, Drug; Harmine; Isoflurane; Lethal Dose 50; Male; Mice, Inbred ICR; Phenytoin; Trihexyphenidyl | 2021 |
Apolipoprotein E epsilon4 and anticholinergic cognitive toxicity.
Topics: Aged; Alleles; Apolipoprotein E4; Cardiovascular Diseases; Cholinergic Antagonists; Cognition Disorders; Cross-Sectional Studies; Humans; Memory Disorders; Muscarinic Antagonists; Trihexyphenidyl | 2009 |